Abstract
Anxiety disorders show striking sex differences in prevalence, symptoms, and clinical characteristics, shaping how they manifest and are experienced. Here, we report the first sex-specific meta-analysis of genome-wide association studies (GWAS) of anxiety, leveraging two of the largest biobank datasets, UK Biobank and All of Us, comprising 85,014 female cases with 130,817 controls and 36,724 male cases with 117,044 controls. Functional annotation, sex-specific polygenic scores (PGS), and genetic correlations were performed to assess genetic differences and functional implications. In females, 26 lead SNPs were significantly associated with anxiety, compared to six in males. Among these, seven lead SNPs in females and five in males demonstrated significantly different effect sizes across sexes. Although the genetic correlation between sexes was high, it was significantly different from one, indicating partially distinct genetic architectures. In addition, both the SNP-based observed and liability-scale heritabilities (assuming a 2:1 female-to-male prevalence ratio) were significantly higher in females. Gene-based tests and functional prioritization identified different genes associated with anxiety in females and males. Moreover, genetic correlation analyses revealed stronger associations of female anxiety with attention-deficit/hyperactivity disorder (ADHD) and body mass index (BMI), whereas male anxiety showed stronger correlations with waist-hip-ratio adjusted BMI. While the overall genetic architecture of anxiety is largely shared, our findings reveal distinct sex-specific genetic associations and correlations, highlighting the value of analysing the sexes separately to uncover genetic signals that may be masked in sex-combined samples.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
J.H was funded by a QIMR PhD scholarship. B.L.M (APP2017176), K.L.G (APP1173025), S.E.M (APP1172917 and APP2025674), and D.C.W (APP2026567) are supported by Investigator Grants from the National Health and Medical Research Council of Australia (NHMRC). E.M.B are supported by Research Excellence grant (1198304) from NHMRC Centre, and the University of Queensland Health Research Accelerator Program. The QSkin Study is supported by a Clinical Trials and Cohort Grant [APP1185416] from NHMRC. PISA was funded by an NHMRC Dementia Research Team Grant [APP1095227]. This study makes use of data from UK Biobank (Project ID: 25331).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Ethics Committee of QIMR Berghofer gave ethical approval P3501, P1309, P2118, P2034 for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This revised version of the manuscript incorporates substantial updates to both the analyses and interpretation. In the original submission, analyses were conducted using the UK Biobank (UKB) cohort only. In this revision, we expanded the scope by performing a meta analysis combining results from the UKB and the All of Us Research Program (AoU). This integration substantially increased the sample size to 369,599 European ancestry individuals, including 121,738 lifetime anxiety cases, thereby improving power to detect associated loci and enabling more robust sex specific comparisons.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
